117 related articles for article (PubMed ID: 35914979)
1. Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis.
Alholm Z; He D; Ting J; Zhang YJ; Sudharshan L; Leong T; Coleman RL; Monk BJ
Gynecol Oncol; 2022 Sep; 166(3):567-575. PubMed ID: 35914979
[TBL] [Abstract][Full Text] [Related]
2. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
Alholm Z; Monk BJ; Ting J; Pulgar S; Boyd M; Sudharshan L; Bains S; Nicacio L; Coleman RL
Gynecol Oncol; 2021 May; 161(2):422-428. PubMed ID: 33741208
[TBL] [Abstract][Full Text] [Related]
3. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer.
Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
J Manag Care Spec Pharm; 2023 May; 29(5):490-498. PubMed ID: 37121257
[No Abstract] [Full Text] [Related]
4. Patient profiles, treatment patterns, and outcomes among persistent, recurrent, or metastatic cervical cancer patients under routine care in the United States.
Gokhale M; Yu R; Monberg M; Tekin C; Chen L; DeClue RW; Knapp K; Lal LS
Cancer Treat Res Commun; 2023; 36():100726. PubMed ID: 37301127
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Tewari KS; Sill MW; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; DiSaia PJ; Copeland LJ; Creasman WT; Stehman FB; Brady MF; Burger RA; Thigpen JT; Birrer MJ; Waggoner SE; Moore DH; Look KY; Koh WJ; Monk BJ
Lancet; 2017 Oct; 390(10103):1654-1663. PubMed ID: 28756902
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
9. Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
Choi HJ; Lee YY; Choi CH; Kim TJ; Lee JW; Bae JH; Bae DS; Kim BG
Curr Probl Cancer; 2020 Oct; 44(5):100557. PubMed ID: 32067746
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
Nadler E; Arondekar B; Aguilar KM; Zhou J; Chang J; Zhang X; Pawar V
J Cancer Res Clin Oncol; 2021 Mar; 147(3):671-690. PubMed ID: 33263865
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
12. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Tinker AV; Fiorino L; O'Dwyer H; Kumar A
Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
15. Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience".
Fagotti A; Conte C; Stollagli F; Gallotta V; Salutari V; Bottoni C; Bruno M; Zannoni GF; Scambia G
Int J Gynecol Cancer; 2018 Oct; 28(8):1569-1575. PubMed ID: 30157167
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
Lester J; Escriu C; Khan S; Hudson E; Mansy T; Conn A; Chan S; Powell C; Brock J; Conibear J; Nelless L; Nayar V; Zhuo X; Durand A; Amin A; Martin P; Zhang X; Pawar V
BMC Cancer; 2021 May; 21(1):515. PubMed ID: 33962574
[TBL] [Abstract][Full Text] [Related]
18. The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Takekuma M; Mori K; Iida T; Kurihara K; Saitou M; Tokunaga H; Kawana K; Ikeda M; Satoh T; Saito T; Miyagi E; Nagai Y; Furusawa A; Kawano Y; Kawano K; Tabata T; Ota Y; Hayase R; Mikami M; Sugiyama T
Cancer Chemother Pharmacol; 2017 Oct; 80(4):697-705. PubMed ID: 28785994
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer.
Yasunaga M; Yahata H; Okugawa K; Shimokawa M; Maeda Y; Hori E; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K
Taiwan J Obstet Gynecol; 2022 Sep; 61(5):818-822. PubMed ID: 36088050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
